MDCX earnings analysis
What we found in MDCX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Medicus Pharma remains a pre-revenue clinical-stage company, with revenue of $0 and Q2 net loss widening to $11,684,427 from $6,176,084 year over year as operating expenses increased 90.8% to $11,478,789. Liquidity improved through $32,354,942 of financing cash flow, but operating cash burn reached $15,953,129 for the first six months and management disclosed substantial going-concern doubt. Clinical and regulatory progress for SkinJect and Teverelix is constructive, but rising R&D needs, new secured debt of $22,864,225, dilution and Nasdaq's $1.00 minimum-bid deficiency keep the risk/reward profile bearish.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue; Loss Expanded Year Over Year
- Revenue remained $0 because the Company does not currently earn revenue from its drug-development programs. Net loss increased to $11,684,427 in Q2 2026 from $6,176,084 in Q2 2025, while diluted loss per share improved to $(0.21) from $(0.43), reflecting share-count dilution.
- Operating Costs Increased Sharply
- Operating expenses rose 90.8% year over year to $11,478,789 in Q2 2026 from $6,016,088. G&A increased 43.6% to $6,571,097 and R&D increased 241.0% to $4,907,692.
- Teverelix Drives R&D Investment
- Six-month R&D expense increased 120.9% to $7,612,085 from $3,445,778, primarily due to Teverelix development. Management expects R&D expenses to increase further as two separate Teverelix Phase 2 trials advance.
- SkinJect Clinical and Regulatory Progress
- SkinJect's Phase 2 SKNJCT-003 dataset showed 55% histological clearance and 64% clinical clearance in the 200-microgram cohort. The FDA also authorized the Gorlin Syndrome Phase 2b study to proceed on July 27, 2026.
- Teverelix Study Size Reduced
- The redesigned Teverelix AUR study is expected to enroll approximately 126 patients, down from approximately 390 patients under the prior development plan, supporting an earlier pharmacodynamic signal and dose optimization.
- Financing Increased Liquidity
- Cash and cash equivalents increased to $15,174,128 at June 30, 2026 from $8,705,218 at December 31, 2025, while restricted cash was $10,017,412. Financing activities generated $32,354,942 during the first six months.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Burn and Going-Concern Risk
- The Company used $15,953,129 in operating cash during the first six months, up from $9,409,825 in the prior-year period. Management states that substantial doubt exists about the Company's ability to continue as a going concern within one year after the financial statements are issued.
- New Secured Debt Raises Leverage
- The May 27, 2026 financing added secured promissory notes with original principal of $22,864,225, including Note A at 8.75% interest and Note B at 5% interest, both maturing November 27, 2027. The notes are secured by company and subsidiary assets, including intellectual property.
- Nasdaq Minimum-Bid Delisting Risk
- Nasdaq notified the Company that its closing bid price had been below $1.00 for 30 consecutive business days. The Company has until October 19, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days.
- Persistent Losses and No Profitability
- The Company had an accumulated deficit of $85,007,966 at June 30, 2026 and reported a six-month net loss of $20,726,738. Management expects significant operating losses for the foreseeable future and may never become profitable.
- Substantial Equity Dilution
- The Company issued 28,248,981 shares under its ATM through June 30, 2026 for gross proceeds of $12,868,181, and had 60,168,044 shares outstanding at quarter-end. Continued equity financing may dilute existing shareholders.
- Clinical and Funding Execution Risk
- Management identifies trial failure, inability to obtain FDA authorization for later-stage development, and inability to secure funding as principal risks. R&D expense was already $7,612,085 for the first six months, with additional spending expected for two Teverelix Phase 2 trials.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.21
- Segment
- SkinJect: six-month external R&D costs were $2,156,515, including $2,011,288 for clinical, manufacturing and regulatory activities.
- Segment
- Teverelix: six-month external R&D costs were $3,928,364, including $3,850,023 for clinical, manufacturing and regulatory activities.
- Segment
- The Company has no commercial revenue from either program; it remains an R&D-stage clinical biotechnology company.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects significant operating losses for the foreseeable future and expects R&D expenses to increase as two Teverelix Phase 2 trials advance.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Medicus Pharma reported a significant net loss, worsening from $5.1 million in Q4 2025 to $9.0 million in Q4 2026. Despite increased cash reserves from equity financings, the company remains without any revenue,…
- 10-K · April 29, 2026
- Medicus Pharma's annual report indicates a focus on positioning itself within the pharmaceutical industry through innovative product development and market expansion. However, the company reported a challenging year…
- 10-K · March 25, 2026
- Medicus Pharma is a clinical-stage, multi-strategy biotech focused on two core assets: SkinJect's doxorubicin microneedle array (D-MNA) for basal cell carcinoma (BCC) and Antev's Teverelix for prostate-related…
- 10-K · March 28, 2025
- Medicus Pharma Ltd. (MDCX) is a pre-revenue biotech focused on a single product candidate, SkinJect (a doxorubicin tip‑loaded dissolvable microneedle array) for basal cell carcinoma. The Phase 1 program completed in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MDCX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever